John Wrangle, MD, MPH
Dr. John Wrangle is a thoracic medical oncologist who specializes in treating non-small cell and small cell lung cancer as well as other thoracic malignancies at the Medical University of South Carolina (MUSC). He is dedicated to bringing novel combination immunotherapy treatments to patient care and has developed precision medicine protocols designed to create additional options for patients so they can avoid poorly tolerated, low-efficacy chemotherapy treatment. The innovations that he introduced at MUSC are now being tested in clinical trials across the United States.[2]
Dr. Wrangle says that “moving from a lab-based Hollings Cancer Center ‘homebrew’ in 2015 to a national concept in 2021 is lightning fast…. Getting a drug used outside of the research environment is a major accomplishment. This is the dream of a cancer researcher – moving a promising therapy from an investigator-initiated trial to the higher-phase clinical trials in order to help more patients.”[2]
Education and Career
Dr. Wrangle earned his medical degree at the Tulane University School of Medicine, and his Master of Public Health at Tulane University School of Public Health and Tropical Medicine. He completed an internship and residency in Internal Medicine at Emory University School of Medicine in Atlanta, Georgia, then completed fellowships in Hematology and Medical Oncology at Johns Hopkins University School of Medicine.[1]
Dr. Wrangle is board-certified in Internal Medicine and Medical Oncology. He has been on staff at the Medical University of South Carolina since 2014 when he completed his medical education and training and currently serves as the SMART State/Burtschy Chair of Thoracic Oncology, working within the Department of Medicine in the Division Hematology/Oncology and the Department of Microbiology and Immunology at the Hollings Cancer Center.
Research
Dr. Wrangle is actively involved in clinical trials and research examining the use of immunotherapy drugs in the treatment of lung cancer and other thoracic malignancies. He is currently recruiting patients with small-cell lung cancer and non-small-cell lung cancer for the studies listed below:[3]
Enrollment Status: Recruiting
Publish Date: November 14, 2023
Intervention Type: Procedure, Drug, Biological
Study Drugs: Carboplatin, Pembrolizumab, Pemetrexed
Enrollment Status: Recruiting
Publish Date: November 13, 2023
Intervention Type: Other, Drug, Radiation, Procedure
Study Drugs: Atezolizumab, Carboplatin, Cisplatin, Etoposide
Enrollment Status: Recruiting
Publish Date: September 15, 2023
Intervention Type: Drug
Study Drug: CLN-081
Enrollment Status: Recruiting
Publish Date: August 29, 2023
Intervention Type: Drug
Study Drug: Screening Platform
Study Phase: Phase 2/Phase 3
Enrollment Status: Recruiting
Publish Date: March 02, 2023
Intervention Type: Drug
Study Phase: Phase 2
Dr. Wrangle is also a published author and co-author documenting the results of his previous research. His most recent publications include:[4]
Novel Collaborations Across Training Programs to Support Mentoring in Sex Differences Research. Aimee L McRae-Clark, Kathleen T Brady, Diana Lee-Chavarria, Jacqueline F McGinty, Kevin M Gray, John Wrangle, Marc Chimowitz>; Journal of Women’s Health. 2023 Aug 1
Safety, Tolerability, and Antitumor Activity of Zipalertinib Among Patients With Non-Small-Cell Lung Cancer Harboring Epidermal Growth Factor Receptor Exon 20 Insertions. Zofia Piotrowska, Daniel Shao-Weng Tan, Egbert F Smit, Alexander I Spira, Danny Nguyen, Victor Ho-Fun Lee, James Chih-Hsin Yang, Vamsidhar Velcheti, John M Wrangle, Ma…>; Journal of Clinical Oncology. 2023 Sep 10
Association of age with survival in older patients with cutaneous melanoma treated with immune checkpoint inhibitors. Ashley V Howell, Mulugeta Gebregziabher, Bruce H Thiers, Evan M Graboyes, Chrystal M Paulos, John M Wrangle, Kelly J Hunt, Kristin Wallace>; Journal of Geriatric Oncology. 2022 Sep 1
